Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 19/20 | 0.55 |
| ▸ | HTR2C | P28335 | 10/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL884166 | 0.84 | HTR2A (0.51) | HTR2AHTR2CKCNH2 | |
| SCHEMBL884673 | 0.84 | HTR2A (0.51) | HTR2AHTR2CKCNH2 | |
| SCHEMBL2063677 | 0.84 | HTR2A (0.78) | HTR2AHTR2CKCNH2 | |
| SCHEMBL2063678 | 0.84 | HTR2A (0.78) | HTR2AHTR2CKCNH2 | |
| SCHEMBL2063651 | 0.84 | HTR2A (0.78) | HTR2AHTR2CKCNH2 | |
| SCHEMBL885530 | 0.81 | HTR2A (0.49) | HTR2AHTR2CKCNH2 | |
| SCHEMBL885413 | 0.81 | HTR2A (0.49) | HTR2AHTR2CKCNH2 | |
| SCHEMBL17119824 | 0.81 | PKM (0.50) | HTR2AHTR2CKCNH2 | |
| SCHEMBL883913 | 0.79 | HTR2A (0.65) | HTR2AHTR2CKCNH2 | |
| SCHEMBL884405 | 0.79 | HTR2A (0.71) | HTR2AHTR2CKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9987252-B2 | Primary amines and derivitves thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9987252-B2 | Primary amines and derivitves thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170189381-A1 | PRIMARY AMINES AND DERIVITVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170189381-A1 | PRIMARY AMINES AND DERIVITVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189381-A1 | PRIMARY AMINES AND DERIVITVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR2A, HTR5A, HTR1A | HTR2A 1/4885HTR2C 7/4885KCNH2 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.